Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 7, 2001

View Archived Issues

First phase III trial starts for NBI-34060 in chronic (primary) insomnia

Cellegy submits NDA supplement for Anogesic

Tetracycline antibiotic finds new use as neuroprotective agent 30 years later

Replicons kill human glioma cells in preclinical study

Immune Network and InNexus continue collaboration on antibodies for HIV

MediGene seeks marketing authorization for Leuprogel in Germany

New immune system role for enzyme with potential in inflammatory diseases discovered at Lexicon

Esperion initiates phase II trial of AIM for acute coronary syndromes

Study shows Combidex can detect malignant lymph nodes in prostate cancer patients

TransTech and Novo Nordisk enter three-year diabetes research collaboration

Abbott acquires control of Vysis

Positive results from phase II trials of HspE7 in HPV-induced sexually transmitted diseases

Tracleer may now be prescribed for PAH patients in U.S.

Cannabinoid receptor agonists especially useful for treating pain and neurodegenerative diseases

Daiichi prepares quinolone antibacterial agents effective in models of pneumonia and sepsis

Phosphoramidate prodrugs enabling enhanced intracellular delivery of drugs

Agents for hepatitis C under study at Vertex

Discovery of novel analgesics reported by AstraZeneca

Evidence pointing to an immunomodulatory mechanism for antiatherosclerotic effects of DiNAC

Na+/H+ exchange inhibitor protects against both normo- and hypothermic cardiac ischemia

SU-11654 inhibits receptor tyrosine kinases, including mutant forms of Kit

Antithrombotic efficacy reported for LB-30870 following parenteral and oral administration

Orally active vanillin prodrug as a potential new sickle cell disease therapy

Thioredoxin-targeting class of antitumor agents synthesized at U.K. university

Tumor-specific immune responses obtained in aggressive NHL patients given idiotype vaccine

Nymox reports discovery of clinical candidate for BPH stemming from AD research

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...